Skip to content
All life stages
Life stage

Sexual dysfunction (libido, arousal)

Reduced libido or arousal, independent of testosterone levels — applies to both sexes.

What changes during this transition

PT-141 (bremelanotide) is the most direct library entry — FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, off-label in men. Acts via melanocortin receptors in the CNS rather than vascular pathways, so it works independent of erectile-physiology issues. Oxytocin has a documented role in arousal and bonding, with off-label use for libido. Kisspeptin via the HPG axis affects libido indirectly through testosterone. Note that libido issues are often multifactorial — relationship dynamics, stress, sleep, and medication side effects (SSRIs especially) account for a large share.

Important caveat

Don't conflate libido with erectile function — they have distinct biology. Erectile dysfunction with adequate libido suggests vascular workup. Libido changes after starting a new medication (especially SSRI / SNRI antidepressants, beta blockers, finasteride) should prompt review of that medication before adding peptides.

Peptides editorially relevant to sexual dysfunction (libido, arousal)

3 peptides from the library — each evidence-tiered honestly.

Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.